Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTAC: hIVIG for Early COVID-19 in Outpatients
NCT04910269Phase 3Terminated
- Sponsor
- University of Minnesota
- Start
- Aug 2021
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Minnesota. Primary endpoint: Clinical Status at 7 days. Started Aug 2021; status: terminated.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04910269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910269.